Biotech startup CARGO Therapeutics looks to land one of the biggest Nasdaq listings in a barren year for life sciences initial public offerings.
If the blood cancer cell therapy maker can garner enough investor intrigue for an IPO at its proposed midpoint price of $16 per share, then its Wall…
Click here to view original post
